Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 24;109(1):98–114. doi: 10.3324/haematol.2023.282704

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 8. — Model for the anti-leukemic activity of TAK-981+5-azacytidine in acute myeloid leukemia. Combined inhibition of SU-MOylation with TAK-981 and DNA methylation with 5-azacytidine (AZA) induces a transcriptional reprogramming in acute myeloid leukemia (AML) cells. This includes the activation of genes involved in the induction of apoptosis and differentiation and a repression of genes linked to cell cycle progression. In addition, TAK-981+AZA induces interferon 1 (IFN-1) secretion as well as the expression of natural killer (NK) cell ligands at the surface of acute myeloid leukemia (AML) cells. This activates NK and increases their cytotoxicity towards AML cells.